These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21478328)

  • 61. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vitamin D in chronic kidney disease: more questions than answers.
    Anker SD; von Haehling S
    JAMA; 2012 Feb; 307(7):722-3. PubMed ID: 22337683
    [No Abstract]   [Full Text] [Related]  

  • 63. A nested group sequential framework for regional evaluation in global drug development program.
    Wang W; Jiang Z; Qiu J; Xia J; Guo X
    J Biopharm Stat; 2017; 27(6):945-962. PubMed ID: 28323515
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sample size re-estimation for clinical trials with longitudinal negative binomial counts including time trends.
    Asendorf T; Henderson R; Schmidli H; Friede T
    Stat Med; 2019 Apr; 38(9):1503-1528. PubMed ID: 30575061
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sample size re-estimation and other midcourse adjustments with sequential parallel comparison design.
    Silverman RK; Ivanova A
    J Biopharm Stat; 2017; 27(3):416-425. PubMed ID: 28166457
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sample size re-estimation in paired comparative diagnostic accuracy studies with a binary response.
    McCray GPJ; Titman AC; Ghaneh P; Lancaster GA
    BMC Med Res Methodol; 2017 Jul; 17(1):102. PubMed ID: 28705147
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study.
    Wych J; Grayling MJ; Mander AP
    Trials; 2019 Dec; 20(1):665. PubMed ID: 31791376
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of high-flow nasal therapy on patient-centred outcomes in patients at high risk of postoperative pulmonary complications after cardiac surgery: a statistical analysis plan for NOTACS, a multicentre adaptive randomised controlled trial.
    Dawson SN; Chiu YD; Klein AA; Earwaker M; Villar SS
    Trials; 2022 Aug; 23(1):699. PubMed ID: 35987698
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adaptive clinical endpoint bioequivalence studies with sample size re-estimation based on a nuisance parameter.
    Zhu L; Sun W
    J Biopharm Stat; 2019; 29(5):776-799. PubMed ID: 31505986
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sample size re-estimation in a breast cancer trial.
    Hade EM; Jarjoura D; Lai Wei
    Clin Trials; 2010 Jun; 7(3):219-26. PubMed ID: 20392786
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sample size re-estimation: recent developments and practical considerations.
    Gould AL
    Stat Med; 2001 Sep 15-30; 20(17-18):2625-43. PubMed ID: 11523073
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sample size estimation and re-estimation of cluster randomized controlled trials for real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests.
    Kada A; Hirakawa A; Kinoshita F; Kobayashi Y; Hatakeyama T; Kobayashi D; Nishiyama C; Iwami T
    Contemp Clin Trials Commun; 2019 Jun; 14():100316. PubMed ID: 31049459
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sample size re-estimation for pivotal clinical trials.
    Liu Y; Xu H
    Contemp Clin Trials; 2021 Mar; 102():106215. PubMed ID: 33217555
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Flexible seamless 2-in-1 design with sample size adaptation.
    Li R; Wu L; Liu R; Lin J
    J Biopharm Stat; 2024 Mar; ():1-19. PubMed ID: 38549502
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sample size re-estimation in clinical trials.
    Wang P; Chow SC
    Stat Med; 2021 Nov; 40(27):6133-6149. PubMed ID: 34433225
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Comparison of Bayesian interim analysis and classical interim analysis in group sequential design].
    Yuan L; Zhan Z; Tan X
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1638-42. PubMed ID: 26607091
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Group sequential designs using a family of type I error probability spending functions.
    Hwang IK; Shih WJ; De Cani JS
    Stat Med; 1990 Dec; 9(12):1439-45. PubMed ID: 2281231
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An Adaptive Three-Arm Comparative Clinical Endpoint Bioequivalence Study Design With Unblinded Sample Size Re-Estimation and Optimized Allocation Ratio.
    Hinds D; Sun W
    Pharm Stat; 2024 Oct; ():. PubMed ID: 39377390
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Not all left ventricular hypertrophy is created equal.
    Klingbeil AU; Schmieder RE
    Nephrol Dial Transplant; 1999 Dec; 14(12):2803-5. PubMed ID: 10570072
    [No Abstract]   [Full Text] [Related]  

  • 80. Blinded sample size re-estimation for comparing over-dispersed count data incorporating follow-up lengths.
    Igeta M; Matsui S
    Stat Med; 2022 Dec; 41(29):5622-5644. PubMed ID: 36148560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.